P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

Introduction. Minimal residual disease (MRD) negativity and sustained MRD negativity are associated with longer survival and are strong prognostic clinical endpoints. PERSEUS (NCT03710603) evaluated subcutaneous Dara + VRd induction/consolidation + DR maintenance vs VRd induction/consolidation + R...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	P. Sonneveld, Ph. Moreau, H. Einsele, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R.L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2026-04-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/14037
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!